Today, Cerebras Systems, the pioneer in high performance AI compute, smashed its previous industry record for inference, ...

Drug safety relates to the potential for adverse effects related to the administration of drugs. Efforts to establish the safely profile of drugs begin early in their development, with in vitro ...

Cerebras Systems' Nasdaq IPO offers an opportunity to buy into a potential challenger to high-flying AI chipmaker Nvidia, though extra scrutiny of its key offshore partner could complicate the timing.

The artificial intelligence boom has been the biggest topic in financial markets for nearly two years, following the November 2022 launch of ChatGPT. And while Nvidia (NASDAQ:NVDA) has been the ...

Help Register Login Login Hi, %{firstName}% Hi, %{firstName}% Games Car rental The Centers for Disease Control and Prevention (CDC) issued a public health warning about prescription medications sold ...

An international team of researchers have made a promising breakthrough in the development of drugs to treat Alzheimer's Disease. For the first time, scientists have developed a drug that works on ...

If Cerebras can grow beyond its initial benefactor, G42, this IPO will be a rocket ship. If not, … It may be hard to believe, but there hasn’t been a single IPO for an AI hardware company ...

And while there are many medications out there to help people cope with pain, they can often cause their own headaches, to say the very least. Now a pharmaceutical company is potentially on the ...

Waferscale compute engine and AI system maker Cerebras Systems has filed with the US Securities and Exchange Commission to sell a chunk of itself to the public, giving we outsiders a view of the past ...